Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity : vimarsana.com

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control. ...

Related Keywords

Harith Rajagopalan , Beth Brett , Timothy Kieffer , Stephen Jasper , Lisa Davidson , Fractyl Health , Exchange Commission , Fractyl Health Inc , Fractyl Health Rejuva , Gilmartin Group , Company Rejuva , Corporate Communications , While The Company , Nasdaq , Fractyl Health Chief Scientific , Clinical Trial Application , Private Securities Litigation Reform Act , Chief Financial Officer ,